Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 30-04 (MA.27) 

A randomized phase III trial of exemestane vs. anastrozole in postmenopausal women with receptor positive primary breast cancer

DESIGN

Please click on the picture to see a larger version

Results & Publications


Presentations


Publications

Study Chairs
IBCSG: Dr. Manuela Rabaglio - Bern, Switzerland
NCIC CTG: Dr. Paul Goss - Boston, USA

Lead Trial Coordinator
Holly Shaw

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg30_MA27@fstrf.org


Date of Activation
April 12, 2005

Date of Closure
December 15, 2006

Targeted Accrual
6840 patients

Final Accrual
7576 patients


Results Publications Results & Publications
Other Pathology


News

14.06.2020:
Save the date and join the IBCSG Pink Ladies! June 14, 2020

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

11.11.2019:
New publications are available 

All News

 
  Print